The Madison Clinic for Pediatric Diabetes is creating GreenDot, an open mobile health platform that enables both patients and health care providers to collect, aggregate, store, analyze and display diabetes-related data wirelessly and in real-time to better control blood sugars. Last month, the Madison Clinic was named one of five finalists in the Sanofi US Innovation Challenge,http://www.datadesigndiabetes.com
Denmark-based pharmaceutical company Novo Nordisk recently awarded Diabetes Center faculty member Fred Schaufele, PhD, with a Diabetes Innovation Award to study the challenge of insulin resistance at the cellular level. Dr. Schaufele seeks to understand why chronically elevated insulin found in patients with insulin resistance causes a dramatic change in insulin receptor structure, leading to even more insulin resistance and ultimately type 2 diabetes.
The Diabetes Teaching Center’s newest innovation, DiabetesIQ, was awarded Outstanding Mobile Application in the Web Marketing Associations’ 2012 MobileWebAward Competition. This free mobile app was created using the educational content found on Diabetes Education Online, www.deo.ucsf.edu, and is available on the Apple iTunes store and Google Android market.
A new study has been launched that seeks to evaluate differences in the immune systems of those who have had type 1 diabetes for five or more years and who still make some insulin, versus those with type 1 diabetes who do not make insulin. It will also establish a blood bank for future studies of type 1 diabetes. Led by pediatric diabetes program director Steve Gitelman, MD, and endocrine fellow Hilary Thomas, MD, the study seeks volunteers who are:
The national research program called Type 1 Diabetes TrialNet recently screened their 100,000th family member for autoantibodies as part of the Natural History Study, now known as the Pathway to Prevention. UCSF is proud to have been selected as one of the first TrialNet Clinical Centers just over a decade ago. For relatives of people with type 1 diabetes who are not yet diagnosed -- but who are at risk for type 1 diabetes -- there are now promising clinical trials available.
The Diabetes Center has created a new industry partnership with international pharmaceutical company, Sanofi. The goal of this alliance is to identify novel therapeutic targets for the creation of new diabetes drugs that will improve the lives of those battling both type 1 and type 2 diabetes.
The aim of a new NIH-funded Health Delivery Systems Center for Diabetes Translational Research is to actively foster and support translational research in type 2 diabetes within health care delivery systems affiliated with the HMO Research Network (HMORN), UCSF and the State of California's Diabetes Prevention and Control Program.
U.S. consumption of sugar has doubled in the past 30 years. Similarly, worldwide consumption of sugar has tripled during the past 50 years and has contributed to 35 million deaths annually from diseases such as diabetes, heart disease and cancer, even in developing countries. Leading experts from throughout UCSF have been making headlines with their urgent societal plea to reduce sugar consumption and ease the burden on public health.
A new faculty member of the Diabetes Center, Shingo Kajimura, PhD, has discovered how to reengineer ordinary white fat into brown fat to help the body burn more calories and lose weight. It is believed that brown fat evolved in man as a protection from the cold. Not only is the amount of brown fat in the body inversely proportional to the likelihood of obesity, we now know that the human body is capable of creating new brown fat cells throughout life.
Our Diabetes Symposium & Kids Kamp held on Saturday, March 10th was a huge success with a capacity crowd of 650 in attendance. This educational program was held in cooperation with the Diabetic Youth Foundation and Mills-Peninsula Health Services.
UCSF Diabetes Center researcher Michael McManus, PhD, and his colleagues at UCSF, the Gladstone Institute for Cardiovascular Disease, and Children's Hospital Oakland Research Institute, have created a new, publicly available resource that will help researchers understand the importance of certain genes in causing diabetes and other diseases.
The UCSF Pancreatic Islet Transplantation Program led by Andrew Posselt, MD, PhD, continues to be very active and, most importantly, very cutting edge. Not only does Dr. Posselt and his team efficiently and effectively harvest islets through their state-of-the-art islet isolation process, they are using new enzymes to ensure islet viability throughout the transplant process.
For relatives of people with type 1 diabetes who are not yet diagnosed, but who are at risk for type 1 diabetes, there are now promising clinical trials available. UCSF Pediatric Diabetes Program Director Stephen Gitelman, MD, suggests that all family members take a simple blood test which screens for the presence of diabetes-related autoantibodies that may appear years before type 1 diabetes develops.